CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®
- The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics
- CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®
- Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer®. The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP-grade RNA vaccines and therapeutics. The new entity is designed as a platform and services company, providing a dedicated operational environment to further develop and establish The RNA Printer® as a manufacturing end-to-end solution. This solution will include the main steps to manufacture mRNA vaccines or therapeutics. The platform is designed to facilitate broad access to mRNA technology and enable mRNA product developments, e.g. for rapid supply of new mRNA-based vaccines in pandemic situations as well as patient access to advanced and personalized mRNA-based therapies in oncology. The company will be led by Dr. Markus Bergmann, who joins CureVac RNA Printer GmbH as General Manager on March 1, 2022.